Literature DB >> 18692085

Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice.

Neil E Rowland1, Erica M Crump, Nancy Nguyen, Kimberly Robertson, Zhuming Sun, Raymond G Booth.   

Abstract

(1R,3S)-(-)-trans-1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene (PAT) is a novel compound that has full-efficacy agonist activity at human 5-HT2C receptors and inverse agonist/antagonist activity at 5HT2A and 5HT2B receptors. In the present paper we describe its effects on food intake in non-deprived C57BL/6 mice adapted to eating a palatable dessert meal each day. PAT showed a dose-related inhibition of food intake with a 50% inhibitory dose of 4.2 mg/kg. The dose-effect curve was similar to that obtained using WAY-161503. Abnormal behaviors were not observed by casual inspection following administration of PAT. The anorectic effect of PAT was additive with that of amphetamine. When PAT, or PAT+amphetamine, were injected 2 h before access to food, most of the anorectic activity had dissipated, indicating that PAT has a biologically effective period of about 1 h. Four daily injections of PAT were associated with some, but not complete loss of the initial anorectic effect; this differs from the rapid tolerance that has been reported to fenfluramine anorexia and suggests that different mechanism(s) are involved in the loss of anorexia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692085      PMCID: PMC3712337          DOI: 10.1016/j.pbb.2008.07.004

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  30 in total

1.  Valvular heart disease associated with fenfluramine-phentermine.

Authors:  H M Connolly; J L Crary; M D McGoon; D D Hensrud; B S Edwards; W D Edwards; H V Schaff
Journal:  N Engl J Med       Date:  1997-08-28       Impact factor: 91.245

2.  Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.

Authors:  M Weintraub; P R Sundaresan; B Schuster; M Moscucci; E C Stein
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

3.  Effect of two types of environmental enrichment for singly housed mice on food intake and weight gain.

Authors:  Kimberly L Robertson; Neil E Rowland
Journal:  Lab Anim (NY)       Date:  2005-10       Impact factor: 12.625

4.  Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.

Authors:  Hans G F Richter; D R Adams; A Benardeau; M J Bickerdike; J M Bentley; T J Blench; I A Cliffe; C Dourish; P Hebeisen; G A Kennett; A R Knight; C S Malcolm; P Mattei; A Misra; J Mizrahi; N J T Monck; J-M Plancher; S Roever; J R A Roffey; S Taylor; S P Vickers
Journal:  Bioorg Med Chem Lett       Date:  2005-12-19       Impact factor: 2.823

5.  Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.

Authors:  A G Saltzman; B Morse; M M Whitman; Y Ivanshchenko; M Jaye; S Felder
Journal:  Biochem Biophys Res Commun       Date:  1991-12-31       Impact factor: 3.575

6.  6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.

Authors:  S M Bromidge; M Duckworth; I T Forbes; P Ham; F D King; K M Thewlis; F E Blaney; C B Naylor; T P Blackburn; G A Kennett; M D Wood; S E Clarke
Journal:  J Med Chem       Date:  1997-10-24       Impact factor: 7.446

7.  Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.

Authors:  Vincent Setola; Malgorzata Dukat; Richard A Glennon; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2005-04-14       Impact factor: 4.436

8.  Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice.

Authors:  S P Vickers; P G Clifton; C T Dourish; L H Tecott
Journal:  Psychopharmacology (Berl)       Date:  1999-04       Impact factor: 4.530

9.  Anorectic efficacy of the fenfluramine/phentermine combination in rats: additivity or synergy?

Authors:  J D Roth; N E Rowland
Journal:  Eur J Pharmacol       Date:  1999-06-04       Impact factor: 4.432

10.  Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors.

Authors:  L H Tecott; L M Sun; S F Akana; A M Strack; D H Lowenstein; M F Dallman; D Julius
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

View more
  13 in total

1.  Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects.

Authors:  Sophie M Banas; Stéphane Doly; Katia Boutourlinsky; Silvina L Diaz; Arnauld Belmer; Jacques Callebert; Corinne Collet; Jean-Marie Launay; Luc Maroteaux
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Effect of serotonergic anorectics on food intake and induction of Fos in brain of mice with disruption of melanocortin 3 and/or 4 receptors.

Authors:  Neil E Rowland; Kaihan J Fakhar; Kimberly L Robertson; Carrie Haskell-Luevano
Journal:  Pharmacol Biochem Behav       Date:  2010-03-27       Impact factor: 3.533

3.  Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.

Authors:  Rajeev Sakhuja; Krishnakanth Kondabolu; Tania Córdova-Sintjago; Sean Travers; Adam S Vincek; Myong Sang Kim; Khalil A Abboud; Lijuan Fang; Zhuming Sun; Clinton E Canal; Raymond G Booth
Journal:  Bioorg Med Chem       Date:  2015-02-07       Impact factor: 3.641

4.  Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation.

Authors:  Clinton E Canal; Tania C Cordova-Sintjago; Nancy Y Villa; Li-Juan Fang; Raymond G Booth
Journal:  Eur J Pharmacol       Date:  2011-10-12       Impact factor: 4.432

5.  The serotonin-2 receptor modulator, (-)-trans-PAT, decreases voluntary ethanol consumption in rats.

Authors:  James Kasper; Rajiv Tikamdas; Myong Sang Kim; Kaley Macfadyen; Richard Aramini; Joseph Ladd; Sarah Bisceglia; Raymond Booth; Joanna Peris
Journal:  Eur J Pharmacol       Date:  2013-09-13       Impact factor: 4.432

6.  Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.

Authors:  Kathryn A Cunningham; Noelle C Anastasio; Robert G Fox; Sonja J Stutz; Marcy J Bubar; Sarah E Swinford; Cheryl S Watson; Scott R Gilbertson; Kenner C Rice; Sharon Rosenzweig-Lipson; F Gerard Moeller
Journal:  ACS Chem Neurosci       Date:  2012-08-11       Impact factor: 4.418

7.  (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.

Authors:  Raymond G Booth; Lijuan Fang; Yingsu Huang; Andrzej Wilczynski; Sashikala Sivendran
Journal:  Eur J Pharmacol       Date:  2009-05-03       Impact factor: 4.432

8.  Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.

Authors:  Drake Morgan; Krishnakanth Kondabolu; Allison Kuipers; Rajeev Sakhuja; Kimberly L Robertson; Neil E Rowland; Raymond G Booth
Journal:  Neuropharmacology       Date:  2013-05-09       Impact factor: 5.250

9.  Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.

Authors:  Clinton E Canal; Tania Cordova-Sintjago; Yue Liu; Myong S Kim; Drake Morgan; Raymond G Booth
Journal:  J Pharmacol Exp Ther       Date:  2013-09-30       Impact factor: 4.030

10.  New Approach to 4-Phenyl-β-aminotetralin from 4-(3-Halophenyl)tetralen-2-ol Phenylacetate.

Authors:  Adam S Vincek; Raymond G Booth
Journal:  Tetrahedron Lett       Date:  2009-09-09       Impact factor: 2.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.